C-50 for Propofol-Remifentanil Target-Controlled Infusion and Bispectral Index at Loss of Consciousness and Response to Painful Stimulus in Chinese Patients: A Multicenter Clinical Trial
机构:[1]Capital Med Univ, Beijing Chaoyang Hosp, Beijing 100020, Peoples R China北京朝阳医院[2]Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100037, Peoples R China[3]Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Chinese Acad Med Sci, Beijing Hosp, Beijing 100037, Peoples R China[5]Capital Med Univ, Beijing Gynecol & Obstet Hosp, Beijing, Peoples R China
BACKGROUND: In this study, we evaluated the predicted blood and effect-site C-50 for propofol and remifentanil target-controlled infusion and the Bispectral Index (BIS) values at loss of consciousness (LOC) and response to a standard noxious painful stimulus in Chinese patients. We hypothesized that these values would be different from previously published data on Caucasians. METHODS: Five medical centers enrolled 405 ASA physical Status I and II unpremedicated Chinese patients (97 men, 308 women) aged 18-65 yr. Propofol was initially given to a predicted blood concentration of 1.2 mu g/mL and thereafter increased by 0.3 mu g/mL every 30 s until Observer's Assessment of Alertness and Sedation score was 1. The propofol was kept constant, and remifentanil was given to provide a predict blood concentration of 2.0 ng/mL, and then increased by 0.3 ng/mL every 30 s until loss of response to a tetanic stimulus. BIS (version 3.22, BIS Quattro sensor) was also recorded. RESULTS: The propofol effect-site C-50 at LOC was 2.2 (2.2-2.3) mu g/mL. The remifentanil effect-site C-50 at loss of response to painful Stimulus was 3.3 ng/mL. Fifty percent of patients lost consciousness at a BIS value of 58, and 95%, had lost consciousness at BIS values <40. The BIS value at C-50 at loss of response to painful stimulus was 65.4, which was higher than that at LOS (P < 0.001). CONCLUSIONS: The predicted blood and effect-site concentrations of propofol and BIS values at LOC were lower than those in previously published studies of Caucasian Populations.
基金:
AstraZeneca Corp. Clinical Research FundAstraZeneca
第一作者机构:[1]Capital Med Univ, Beijing Chaoyang Hosp, Beijing 100020, Peoples R China
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Chaoyang Hosp, Beijing 100020, Peoples R China[*1]Capital Med Univ, Beijing Chaoyang Hosp, 8 Baijiazhuang Rd, Beijing 100020, Peoples R China
推荐引用方式(GB/T 7714):
Xu Zhipeng,Liu Fang,Yue Yun,et al.C-50 for Propofol-Remifentanil Target-Controlled Infusion and Bispectral Index at Loss of Consciousness and Response to Painful Stimulus in Chinese Patients: A Multicenter Clinical Trial[J].ANESTHESIA AND ANALGESIA.2009,108(2):478-483.doi:10.1213/ane.0b013e31818f8a30.
APA:
Xu, Zhipeng,Liu, Fang,Yue, Yun,Ye, Tiehu,Zhang, Bingxi...&Che, Xiangming.(2009).C-50 for Propofol-Remifentanil Target-Controlled Infusion and Bispectral Index at Loss of Consciousness and Response to Painful Stimulus in Chinese Patients: A Multicenter Clinical Trial.ANESTHESIA AND ANALGESIA,108,(2)
MLA:
Xu, Zhipeng,et al."C-50 for Propofol-Remifentanil Target-Controlled Infusion and Bispectral Index at Loss of Consciousness and Response to Painful Stimulus in Chinese Patients: A Multicenter Clinical Trial".ANESTHESIA AND ANALGESIA 108..2(2009):478-483